# Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06890598/  
OnCo record `nct06890598` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olomorasib, Pembrolizumab and Durvalumab in non-small-cell lung cancer, run by Eli Lilly and Company, now recruiting.

## Summary

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06890598 by Eli Lilly and Company, with 700 participants planned, started 2025-03-27 and due to reach its primary completion in 2029-05. Interventions recorded: Olomorasib, Pembrolizumab, Durvalumab and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06890598
- Phase: 3
- Setting: A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
- Sponsor: Eli Lilly and Company
- Enrolled: 700

## Sources

- ClinicalTrials.gov NCT06890598: https://clinicaltrials.gov/study/NCT06890598

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct06890598.json